Comprehensive Analysis of D-Allulose Production: A Review and Update

If you formulate with allulose, you already know the bottleneck. Production economics hinge on enzyme performance. A review in Foods (DOI: 10.3390/foods13162572) maps how fast that picture is changing. The paper focuses on enzymatic conversion, and it gives buyers a useful lens for sourcing decisions.

The regulatory door opened

Allulose sits in a stronger position than it did a few years ago. In 2019, the FDA recognized allulose as GRAS. China’s NHC has also approved it as a new food ingredient. For formulators, that means regulatory cover in two major markets. The conversation has shifted from “can we use it?” to “can we make enough of it at the right price?”

What the study did

The authors reviewed recent advances in D-allulose production. They concentrated on enzymatic conversion methods rather than chemical synthesis. Four areas get most of the attention: immobilization, novel enzyme discovery, directed evolution, and metabolic pathway modification. Each one attacks a different cost driver.

Immobilization makes enzymes reusable. Novel enzyme discovery finds new ketose 3-epimerases with more desirable properties. Directed evolution improves stability and activity in the lab. Metabolic pathway modification moves production into whole cells. Together, these approaches form a toolkit for scaling allulose.

Key findings

The clearest performance data in the paper comes from a multi-enzyme cascade applied to juice biotransformation. The system converted D-fructose to D-allulose at a 75% conversion rate, with a 60% total yield. That number matters.

Approach	Why It Matters
Enzyme immobilization	Reusable catalysts reduce enzyme cost per batch
Novel enzyme discovery	New epimerases broaden process conditions
Directed evolution	Lab-evolved enzymes improve stability and activity
Metabolic pathway modification	Whole-cell biosynthesis can use cheaper feeds
Multi-enzyme cascade	75% conversion, 60% total yield in juice

Read the table as a supply signal. Suppliers using older single-enzyme processes may not hit those numbers. Suppliers with cascade or engineered systems likely have a real cost advantage. Ask them how they produce allulose and what yield they guarantee.

What it means for manufacturers

Regulatory approval removes a major barrier. The GRAS status from the FDA and China’s new food ingredient approval mean you can formulate with allulose in mainstream products. The remaining challenge is cost.

The 75% conversion figure gives you a benchmark. If you are evaluating ingredient suppliers, ask how their enzymatic process compares. A supplier that cannot tell you conversion rate or total yield may be working with outdated technology. Your finished product cost depends on their enzyme efficiency.

This review also points to supply diversification. Because multiple enzymatic routes now exist, allulose production is not locked into one method. That is good news for buyers. More routes mean more potential suppliers and more pricing pressure in your favor.

FAQ

Is allulose GRAS in the United States? Yes. The FDA recognized allulose as GRAS in 2019. That opened the door for its use in a wider range of food products.

Can allulose be made from fructose efficiently? Yes. The multi-enzyme cascade described in this review achieved a 75% conversion from D-fructose and a 60% total yield. Inefficiency remains, but the process is viable.

What should I ask an allulose supplier? Ask about their enzyme platform. Specifically ask if they use immobilized enzymes, engineered enzymes, or a cascade. Then ask for conversion rate, total yield, and regulatory documentation.

The science behind allulose production is moving quickly. Buyers who track enzyme technology will find better pricing and more stable supply. The next few years will not look like the last.